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Introduction: Advanced atherosclerotic lesions are characterized by lipid accumulation, inflammation, and
defective efferocytosis. An ideal therapy should address all aspects of this multifactorial disease. Ixmyelocel-T
therapy, an expanded autologous multicellular therapy showing clinical promise in the treatment of diseases
associated with advanced atherosclerosis, includes a novel population of M2-like macrophages. Here, we examine
the macrophages of ixmyelocel-T and determine their ability to influx modified cholesterol in an atheroprotective
manner, maintaining cholesterol homeostasis and preventing cellular dysfunction and death, ultimately promoting
reverse cholesterol efflux.
Methods: Approximately 50 ml of whole bone marrow was obtained from healthy donors and shipped overnight.
Bone marrow mononuclear cells (BMMNCs) were produced by using density gradient separation and cultured for
approximately 12 days to generate ixmyelocel-T. CD14+ cells were isolated from ixmyelocel-T via positive selection
for analysis. Ixmyelocel-T and human leukemia monocyte (THP-1) cells were loaded with acetylated low-density
lipoprotein (Ac-LDL) for analysis. Flow cytometry and immunofluorescence were used to examine Ac-LDL uptake,
expression of cytokines was analyzed by enzyme-linked immunofluorescence assay (ELISA), and quantitative real-
time PCR was used to analyze expression of cholesterol-transport genes. Both the in vitro cholesterol efflux assay
and in vivo reverse cholesterol transport assay were used to examine cholesterol transport.
Results: Ixmyelocel-T macrophages take up acetylated low-density lipoprotein and express the scavenger receptors
CD36 and scavenger receptor-B1 (SR-B1). Ixmyelocel-T did not become apoptotic or proinflammatory after lipid load-
ing. The cholesterol transporter genes ABAC1 and ABCG1 were both statistically significantly upregulated when
ixmyelocel-T macrophages were loaded with cholesterol. Ixmyelocel-T also exhibited enhanced apolipoprotein A-I
(ApoAI)-mediated cholesterol efflux. In addition, in vivo reverse cholesterol-transport assay demonstrated that
ixmyelocel-T was able to efflux cholesterol in this model.
Conclusions: Ixmyelocel-T macrophages influx modified cholesterol, remained anti-inflammatory in the face of lipid
loading and inflammatory challenge, and displayed enhanced cholesterol efflux capabilities. These combined
features suggest that this autologous multicellular therapy may exert beneficial effects in atherosclerotic diseases.Introduction
Atherosclerosis, a chronic inflammatory disease of the
vessel wall, is a leading cause of death in developed
countries [1]. Accumulation of lipid-loaded macrophage
foam cells is a central feature in the formation of athe-
rosclerosis. Macrophages, the most abundant cell type in
atherosclerotic lesions, accumulate lipids, secrete in-
flammatory cytokines, and participate in all phases of
atherosclerosis [2]. Maintaining macrophage cholesterol* Correspondence: rbartel@aastrom.com
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reproduction in any medium, provided the orhomeostasis is essential in preventing the pathogenesis
of atherosclerosis [3]. Macrophage-scavenger receptors,
such as scavenger receptor (SR)-A and CD36, mediate
the unregulated uptake of modified LDL lipoproteins,
which leads to foam cell formation [3-5]. Cholesterol ef-
flux, which removes excess cholesterol from macropha-
ges, is believed to be the major process involved in the
regression of atherosclerotic lesions [6,7]. The net flux,
or influx and efflux, of modified cholesterol plays a key
role in maintaining cholesterol homeostasis in macro-
phages [8]. An imbalance between cholesterol uptake by
scavenger receptors and efflux in macrophages is widelyl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gression of atherosclerosis [3,9].
Macrophage cholesterol efflux is considered to be pro-
tective against the development of atherosclerosis [10].
Free or unesterified cholesterol (FC) is toxic to macro-
phages and can lead to apoptosis [11]. To prevent cell
death, cholesterol is stored as cholesterol esters (CEs)
within macrophage foam cells and effluxed as FC. Cho-
lesterol efflux is mediated by the ATP-binding cassette
transporters ABCA1 and ABCG1 [3]. ABCA1 regu-
lates cholesterol efflux to lipid-free apolipoprotein A-I
(apoA-I), and ABCG1 regulates cholesterol efflux to
high-density lipoprotein (HDL) [12,13]. Both ABCA1
and ABCG1 prevent cholesterol accumulation and play
an important role in maintaining macrophage choles-
terol homeostasis. Excess ingested cholesterol is esteri-
fied by acyl-CoA:cholesterol acyl-transferase 1 (ACAT-1)
and stored as lipid droplets in macrophages [3]. Cholesterol
ester hydrolase (CEH) releases free cholesterol from stored
CE, allowing it to be removed from macrophages through
cholesterol efflux [5]. Studies have shown that macrophages
with high CEH activity accumulate fewer CEs. Promoting
macrophage cholesterol efflux could prevent progression
or induce regression of atherosclerosis [11].
Macrophages are a diverse population of cells that
adapt and respond to a variety of signals, including cyto-
kines and microbial products [14]. Classically activated
macrophages, or M1, produce proinflammatory cyto-
kines and kill microorganisms [14], whereas alternatively
activated macrophages, or M2, regulate the inflamma-
tory response by producing antiinflammatory cytokines,
scavenging debris, and promoting tissue repair [14-18].
Both populations are considered extremes of a wide var-
iety of macrophage phenotypes [19]. Atherosclerotic pla-
ques have been found to contain a mixture of M1 and
M2 macrophages [20,21]. Recent studies have suggested
that M1 macrophages are dominant in both initial and
developing atherosclerotic lesions, whereas M2 macro-
phages are associated with lesion regression [20,22,23].
It is thought that M2 macrophages may help prevent
lesion progression by secreting antiinflammatory cyto-
kines, such as interleukin (IL)-10, and efficiently re-
moving apoptotic cells [20].
Ixmyelocel-T is an expanded autologous multicellular
therapy containing a combination of cell types derived
from cultured bone marrow mononuclear cells [24].
Ledford KJ, Murphy N, Zeigler F, Bartel RL (unpublished
data) found that ixmyelocel-T contains a population of
unique M2-like macrophages that are characterized by
secretion of the antiinflammatory cytokines IL-10 and
IL-1ra, with minimal secretion of the proinflammatory
cytokines tumor necrosis factor-alpha (TNF-α) and IL-12
after inflammatory challenge (Ledford KJ, Murphy N,
Zeigler F, Bartel RL, unpublished data). Furthermore,these macrophages have demonstrated efferocytosis
(that is, efficient removal of apoptotic cells) (Ledford KJ,
et al., unpublished data). Both of these characteristics
have been hypothesized to have beneficial effects in the
treatment of atherosclerosis: IL-10 inhibits the secre-
tion of inflammatory cytokines from other cells [20],
and efferocytosis is considered atheroprotective [20].
Defective efferocytosis has been shown to promote
atherosclerosis [25].
The goal of this investigation was to examine further
ixmyelocel-T macrophages and determine the ability of
these cells to influx/efflux modified cholesterol in an
atheroprotective manner, by maintaining cholesterol ho-
meostasis and preventing cellular dysfunction and death,
ultimately promoting reverse cholesterol efflux.
In this study, THP-1 macrophages were used as a con-
trol in these investigations. THP-1 cells are commonly
used as a model to delineate macrophage gene expres-
sion and functions associated with modified cholesterol
loading and have been established as an effective model
to study the effects of cholesterol homeostasis [26-29].
Methods
Cell culture
For the generation of ixmyelocel-T, commercially avai-
lable bone marrow aspirates (Lonza, Walkersville, MD,
USA) were obtained from healthy donors under in-
formed consent. A small amount (about 50 ml) of whole
bone marrow was obtained through needle aspiration of
the posterior iliac crest, and stored in heparinized tubes.
The mononuclear cell fraction was obtained through an
automated, closed-system, Ficoll-based density gradient
centrifugation separation process. The isolated mono-
nuclear cells were then transferred to a sterile, single-use
cell cassette [30]. This proprietary system controlled
temperature, culture-medium exchange, and gas exchange
during the culture period. After approximately 12 days,
the cells were washed and harvested from the cassette by
a multistep, automated process. The cells were then used
for experimental study.
THP-1 cells were obtained from ATCC (Manassas,
VA, USA) and cultured in RPMI 1640 (ATCC) contai-
ning 10% fetal bovine serum and 2 mM L-glutamine,
according to the manufacturer’s instructions. THP-1
monocytes were differentiated into macrophages by
using 200 nM phorbol myristate acetate (InvivoGen, San
Diego, CA, USA) for 3 days, after which they were used
in the following experiments.
CD14+ cell purification
CD14+ cells were isolated from ixmyelocel-T by posi-
tive selection by using MACS beads (Miltenyi Biotec,
Bergisch Gladbach, Germany), according to the manu-
facturer’s directions. After positive selection, the CD14+
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culture plates for subsequent experiments.
Dil-Ac-LDL immunostaining
For fluorescent imaging, CD14+ ixmyelocel-T and THP-1
macrophages were plated in glass-chamber slides and
allowed to adhere. Cells were loaded with 10 μg/ml Dil-
Ac-LDL in serum-free media containing 0.2% bovine
serum albumin (BSA; fatty acid free; Sigma-Aldrich, St.
Louis, MO, USA). After 24 hours, the cells were washed
with phosphate-buffered saline (PBS) and fixed in 10% for-
malin for 10 minutes. Counterstaining was performed
with DAPI to visualize nuclei. Fluorescent images were vi-
sualized by using a Nikon Eclipse 80i (Nikon, Melville,
NY, USA) equipped with an EXi Aqua Bio-Imaging
Microscopy Camera (Q Imaging, Surrey, BC, Canada).
For flow-cytometry quantification of ac-LDL uptake,
ixmyelocel-T and THP-1 macrophages were loaded
with 10 μg/ml Dil-Ac-LDL in serum-free media. DiI-
AcLDL uptake was analyzed with flow cytometry with
at least 10,000 events acquired for each sample. DiI-
AcLDL uptake was quantified by mean fluorescent inten-
sity, which was calculated by dividing the value of positive
gated events by the value of the negative population.
Cytokine secretion
Enzyme-linked immunosorbent assay kits were used
to determine the concentrations of IL-1β, TNF-α, IL-6,
and monocyte chemoattractant protein (MCP)-1 (R&D
Systems, Minneapolis, MN, USA). In brief, CD14+
ixmyelocel-T and THP-1 macrophages were loaded with
50 μg/ml acetylated low-density lipoprotein (Ac-LDL;
Fisher Scientific, Pittsburg, PA, USA) for 24 hours in
serum-free media containing 0.2% BSA (fatty acid free).
After 24 hours, the cells were washed with PBS and trea-
ted with lipopolysaccharide (LPS; 0.1 μg/ml) overnight.
Supernatants were then collected and assayed by following
manufacturer’s directions. For cytokine analysis, the values
were normalized to cell number.
Apoptosis assay
Apoptosis was measured in both ixmyelocel-T and THP-
1 macrophages loaded with Ac-LDL. In brief, cells were
seeded in 96-well plates and loaded with 100 μg/ml
Ac-LDL for 24 hours in serum-free media containing
0.2% BSA (fatty acid free). The concentration of Ac-LDL
used to induce apoptosis was based on our preliminary
dose-finding study, which demonstrated that loading
with 100 μg/ml Ac-LDL induced apoptosis in THP-1
macrophages. Induction of apoptosis was examined by
measuring the caspase-3 and caspase-7 activity with the
Caspase-Glo 3/7 Assay (Promega). Luminescence units
were measured by using a SpectraMax plate reader
(Molecular Devices, Sunnyvale, CA, USA), and valueswere expressed as a percentage relative to the values ob-
tained from the control group (THP-1 macrophages).
Cholesterol-efflux assay
Ixmyelocel-T and THP-1 macrophages were plated at
0.5 × 106 cells/well, labeled with 3H-cholesterol for 24
hours, and allowed to equilibrate overnight. Cholesterol
efflux was measured by using 20 μg/ml apoA-I and 20
μg/ml HDL3 in acceptor media after 4 hours. The efflux
media and cells were analyzed to determine the percent-
age of cholesterol release.
Reverse cholesterol transport
Experiments were performed in severe combined immu-
nodeficient (SCID) mice (n = 10). In brief, 3H-choles-
terol-labeled ixmyelocel-T (n = 3) and J774 cells (3 to
5 × 106) 0.5 ml MEM-HEPES were injected intraperito-
neally. Blood was collected at 24 and 48 hours, and
plasma was used for scintillation counting. Feces were
collected continuously for 48 hours and used for scintil-
lation counting.
Real-time PCR
Both CD14+ ixmyelocel-T and THP-1 macrophages were
loaded with 50 μg/ml Ac-LDL for 24 hours in serum-
free media containing 0.2% BSA (fatty acid-free). After
24 hours, the cells were washed with PBS and harvested
for RNA isolation. For real-time PCR, total RNA was ex-
tracted with an RNeasy Mini kit (Qiagen, Valencia, CA,
USA), and 1 μg of RNA was reverse transcribed by using
the high-capacity cDNA reverse transcription kit per
the manufacturer’s directions (Applied Biosciences,
Carlsbad, CA, USA). Relative levels of target-gene ex-
pression were measured on the 7500 Real-Time PCR
system (Applied Biosystems). FAM-based Taqman Gene
Expression Assay Mix (Applied Biosystems) specific for
each gene of interest and Taqman Universal Master Mix
(Applied Biosystems) were used. Relative quantification
PCR analysis was performed by using the ABI 7500 Soft-
ware (Applied Biosystems). The relative amount of cDNA
was calculated by normalization to GAPDH.
Statistical analysis
Paired t tests were performed to compare results. A
P value less than 0.05 was considered statistically sig-
nificant. Data are reported as mean ± SEM.
Results
Ixmyelocel-T macrophages influx modified cholesterol
The ability to ingest modified cholesterol and the degree
of Ac-LDL accumulation was examined with fluorescent
microscopy and flow cytometry by using Dil-Ac-LDL
(Figure 1). Fluorescent microscopy revealed that the THP-1


























































































Figure 1 Ixmyelocel-T macrophages influx modified cholesterol. (A) Fluorescent microscopy images and (B) flow-cytometry analysis
(n ≥ 5) of ixmyelocel-T and THP-1 macrophages loaded with Dil-Ac-LDL. Quantitative real-time PCR gene-expression analysis of scavenger
receptors normalized to GAPDH (n ≥ 5). Expression of (C) CD36 and (D) SCARB1 in THP-1 and ixmyelocel-T macrophages before and after
lipid loading. Values are presented as mean ± SEM relative to control; *P < 0.01 versus THP-1 -Ac–LDL, **P < 0.001 versus THP-1 -Ac–LDL.
Magnification: 40×. Dil-Ac-LDL, low-density lipoprotein from human plasma, acetylated, Dil complex; PCR, polymerase chain reaction;
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; SCARB1, scavenger receptor class B type I; SEM, standard error of the mean; Ac-LDL,
acetylated low-density lipoprotein.
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macrophages loading with Dil-Ac-LDL appeared to be
loaded with smaller lipid droplets (Figure 1A). Flow cy-
tometry revealed that both ixmyelocel-T and THP-1 ingest
similar amounts of Dil-Ac-LDL (257 ± 13 versus 246 ± 10
mean fluorescent intensity; P = 0.26; compared with
THP-1; Figure 1B). These results provide evidence that
ixmyelocel-T macrophages do influx modified cholesterol.
These results also suggest that ixmyelocel-T macrophages
do not store large droplets, or pools, of cholesterol.
To understand further the mechanisms of Ac-LDL
uptake, real-time PCR was used to examine expression
of the modified lipid-scavenger receptors CD36 andscavenger receptor (SR)-B1 before and after lipid loading
with Ac-LDL. No statistically significant increase in
CD36 expression was found after lipid loading in either
ixmyelocel-T or THP-1 macrophages. THP-1 cells ex-
hibited increased expression of SR-B1 after lipid loa-
ding (1.44 ± 0.11 versus 1 ± 0.05-fold change, P < 0.01,
compared with THP-1-Ac–LDL; Figure 1D), whereas no
change in expression of SR-B1 occurred in ixmyelocel-T
macrophages treated with Ac-LDL (0.16 ± 0.04 versus
0.21 ± 0.05-fold change; P =NS compared with ixmyelocel-
T +Ac-LDL; Figure 1D). These data suggest that ixmye-
locel-T macrophages influx Ac-LDL through scavenger
receptors that ingest modified lipids.
Table 1 Ixmyelocel-T secretes minimal amounts of
proinflammatory cytokines after lipid loading
THP-1 (−LPS) THP-1 (+LPS) IXT (−LPS) IXT (+LPS)
IL-1β 25.7 ± 6 13,213 ± 269a 2.2 ± 0.8b 10 ± 1.9a
TNF-α 135 ± 30 67,063 ± 8,539a 86 ± 54 151 ± 80a
IL-6 97 ± 19 15,733 ± 1,874a 769 ± 353c 2,376 ± 551ad
MCP-1 940 ± 120 29,611 ± 2,713a 5,575 ± 1,912c 8,480 ± 2,491a
Cytokines were quantified in supernatants from lipid-loaded ixmyelocel-T and
THP-1 macrophages treated with and without LPS (n ≥ 6). The amount of
cytokine expressed was normalized to the cell number of each sample. Values
are presented as mean ± SEM relative to control. aP < 0.001 versus THP-1 - LPS;
bP < 0.01 versus THP-1 - LPS. cP < 0.05, LPS, lipopolysaccharide; SEM, standard
error of the mean; IXT, ixmyelocel-T. dP < 0.05 versus IXT -LPS.
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loading
To determine if lipid loading resulted in apoptosis, both
ixmyelocel-T and THP-1 macrophages were loaded with
100 μg/ml Ac-LDL for 24 hours. Apoptosis was then an-
alyzed by using a luminometric caspase 3/7 assay, which
examines activation of caspases-3 and −7. As shown in
Figure 2, THP-1 macrophages exhibited a statistically
significant higher level of Ac-LDL-induced apoptosis
(114% ± 3.58% versus 100% ± 3.58% of control; P < 0.01
compared with THP-1 -Ac–LDL; Figure 2), than ixmye-
locel-T (87% ± 10.78% versus 100% ± 14.58% of control;
P =NS compared with ixmyelocel-T -Ac–LDL; Figure 2).
Ixmyelocel-T secretes minimal amounts of
pro-inflammatory cytokines after lipid loading
When macrophages are unable to maintain cholesterol
homeostasis because of ineffective cholesterol efflux, a
proinflammatory response is generated [5]. Therefore,
IL-1β, TNF-α, IL-6, and MCP-1 secretion was measured
in lipid-loaded THP-1 and ixmyelocel-T macrophages
before and after LPS stimulation (Table 1). When stimu-
lated with LPS, THP-1 macrophages secreted signi-
ficantly elevated amounts of IL-1β, TNFα, IL-6, and
MCP-1 (Table 1). When ixmyelocel-T macrophages were
stimulated with LPS, a statistically significant increase in
IL-6 was found; however, the level of IL-6 is lower com-
pared with those from THP-1 macrophages (Table 1).
Overall, THP-1 macrophages secreted significantly higher
amounts of the inflammatory cytokines after LPS stimula-
tion compared with ixmyelocel-T macrophages. THP-1
macrophages exhibited a 514-fold increase for IL-1β, a
497-fold increase for TNF-α, a 162-fold increase for IL-6,
and a 32-fold increase for MCP-1 (Table 1). However,
ixmyelocel-T macrophages exhibited a fivefold increase
for IL-1β, a twofold increase for TNF-α, a threefold
increase for IL-6, and a 1.5-fold increase for MCP-1





























Figure 2 Ixmyelocel-T is not sensitive to modified cholesterol-
induced lipotoxicity; percentage of apoptosis after cholesterol
loading. Values are presented as mean ± SEM relative to control;
*P < 0.01 versus THP-1 -Ac–LDL. SEM, standard error of the mean;
Ac-LDL, acetylated low-density lipoprotein.macrophages remain antiinflammatory even after lipid
loading.
Ixmyelocel-T displays enhanced cholesterol-efflux
capacity
With real-time PCR, expression of key genes involved in
cholesterol efflux (for example, ABCA1 and ABCG1)
was examined with and without cholesterol loading.
There was a statistically significant increase in expres-
sion of ABCA1 in ixmyelocel-T macrophages after chol-
esterol loading (1.49 ± 0.32 versus 0.42 ± 0.11-fold
change; P < 0.01 compared with ixmyelocel-T -Ac–LDL;
Figure 3A), whereas ABCA1 was significantly decreased
in THP-1 macrophages loaded with cholesterol (0.78 ±
0.05 versus 1 ± 0.07-fold change, P < 0.05 compared with
THP-1 -Ac–LDL; Figure 3A). Additionally, ixmyelocel-T
macrophages expressed significantly more ABCA1 after
lipid loading compared with THP-1 macrophages (1.49 ±
0.32 versus 0.78 ± 0.05-fold change, P < 0.05 compared
with THP-1 + Ac-LDL; Figure 3A). Expression of ABCG1
was significantly increased in ixmyelocel-T macrophages
after cholesterol loading (0.41 ± 0.13 versus 0.07 ± 0.03-
fold change, P < 0.05 compared with ixmyelocel-T -Ac–
LDL; Figure 3B), whereas ABCG1 was significantly
decreased in THP-1 macrophages loaded with choles-
terol (0.75 ± 0.04 versus 1 ± 0.04-fold change, P < 0.001
compared with THP-1 -Ac–LDL; Figure 3B).
ACAT1 and CEH were also examined in both cell
populations. Ixmyelocel-T macrophages expressed sig-
nificantly lower ACAT1 compared with THP-1 macro-
phages (0.56 ± 0.08 versus onefold ± 0.03-fold change,
p < 0.001 compared with THP-1 -Ac–LDL; Figure 3C).
After lipid loading, no change was seen in ACAT1 ex-
pression in ixmyelocel-T macrophages (0.63 ± 0.11-fold
versus 0.56- ± 0.08-fold change, P =NS compared with
ixmyelocel-T -Ac–LDL; Figure 3C), whereas THP-1 mac-
rophages expressed significantly elevated levels of ACAT1
(1.2-fold ± 0.03-fold versus onefold ± 0.03-fold change,
P < 0.001 compared with THP-1 -Ac–LDL; Figure 3C).
After lipid loading, a statistically significant increase in


































































































































Figure 3 Ixmyelocel-T displays enhanced cholesterol-efflux capacity. Quantitative real-time PCR gene-expression analysis of scavenger
receptors normalized to GAPDH (n ≥ 5). Expression of (A) ABCA1, (B) ABCG1, (C) ACAT1, and (D) CEH in THP-1 and ixmyelocel-T macrophages
before and after lipid loading. (E) Cholesterol efflux of both THP-1 macrophages and ixmyelocel-T to the lipid acceptors ApoA-I and HDL3 (n ≥ 4).
Values are presented as mean ± SEM relative to control; *P < 0.05, **P < 0.01, ***P < 0.001 versus THP-1 -Ac–LDL; #P < 0.05, ##P < 0.01 versus IXT -Ac–LDL.
PCR, polymerase chain reaction; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ABC, ATP-binding cassette; ACAT, acyl-CoA:cholesterol
acyl-transferase; CEH, cholesterol ester hydrolase; ApoA-I, apolipoprotein A-I; HDL, high-density lipoprotein; SEM, standard error of the mean; Ac-LDL,
acetylated low-density lipoprotein.
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compared with ixmyelocel-T -Ac–LDL; Figure 3D),
whereas THP-1 macrophages expressed significantly de-
creased levels of CEH (0.71 ± 0.03-fold versus 1-fold ±
0.06-fold change, P < 0.001 compared with THP-1 -Ac–
LDL; Figure 3D). Because these genes, which are involved
in cholesterol efflux, were upregulated in ixmyelocel-T, an
in vitro cholesterol efflux assay was used to determine the
ability of both cells to efflux cholesterol. Apolipoprotein
A-I (ApoA-I)-mediated cholesterol efflux was significantly
higher in 3H-cholesterol-AcLDL-loaded ixmyelocel-T
compared with THP-1 macrophages (13.91% ± 1.90%
versus 3.42% ± 0.31%, P < 0.001 compared with THP-1;Figure 3E). HDL3-mediated cholesterol efflux was signifi-
cantly higher in 3H-cholesterol-AcLDL-loaded ixmyelocel-
T compared with THP-1 macrophages (2.58% ± 0.052%
versus 0.85% ± 0.09%, P < 0.01 compared with THP-1;
Figure 3E). Collectively, these data indicate that ixmyelo-
cel-T macrophages exhibit enhanced capacities to efflux
cholesterol.
Ixmyelocel-T promotes reverse cholesterol transport
The classic reverse cholesterol transport (RCT) pathway
involves cholesterol efflux from macrophage foam cells
to cholesterol acceptors and the excretion of cholesterol
into the feces [11,31]. The in vivo RCT assay was used
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capable of effluxing cholesterol in vivo. As shown in
Figure 4, ixmyelocel-T is capable of promoting RCT
in vivo. After injection of 3H-cholesterol-labeled ixmye-
locel-T into the peritoneal cavity of SCID mice, plasma
3H-cholesterol levels were similar to the control cell line
J774 cells after both 24 hours (3.21% ± 0.23% versus
3.48% ± 0.39% injected cpm, p =NS compared with J774;
Figure 4A) and 48 hours (2.92% ± 0.22% versus 2.51% ±
0.22% injected cpm, P = NS compared with J774;
Figure 4A). Statistically significantly more 3H-tracer
was found in the livers of mice injected with ixmye-
locel-T compared with the J774 cells (5.49% ± 0.30%
versus 3.79% ± 0.39% injected cpm, P < 0.05 compared
with J774; Figure 4B), and no difference was found
in the feces (4.16% ± 0.14% versus 4.85% ± 0.57% in-
jected cpm, P = NS compared with J774; Figure 4C).
These data demonstrate that ixmyelocel-T is able to
efflux cholesterol in vivo, promoting cholesterol ef-
flux in this model.
Discussion
The current study provides evidence that ixmyelocel-T
macrophages influx and efflux modified cholesterol























Figure 4 Ixmyelocel-T promotes reverse cholesterol transport. In vivo
injections of either 3H-cholesterol-loaded J774 cells or ixmyelocel-T. (A) Pla
the liver, and (C) 3H-tracer found in the feces after 48 hours (n≥ 3 per grou
versus J774. SCID, severe combined immunodeficient; SEM, standard errorixmyelocel-T macrophages help maintain cellular choles-
terol homeostasis, preventing cellular dysfunction and
death, and ultimately promoting reverse cholesterol efflux.
These data point to a potential new innovative application
of ixmyelocel-T in the treatment of atherosclerotic dis-
eases where massive amounts of modified cholesterol are
present. Not only are ixmyelocel-T macrophages less sus-
ceptible to becoming foam cells, but they also appear to
house the biologic machinery necessary to promote RCT,
which has the potential to prevent progression or induce
regression of atherosclerosis.
Uncontrolled accumulation of modified lipids in mac-
rophages is a continuous process that contributes to all
stages of atherosclerosis. Expression of scavenger recep-
tors on macrophages is not downregulated by the accu-
mulation of intracellular lipids, resulting in uncontrolled
lipid accumulation and eventual irreversible cell damage
and death [32]. This study and previously reported data
(Ledford et al., unpublished data) demonstrated that
ixmyelocel-T macrophages express relatively low levels
of surface receptors involved in the uptake of modified
cholesterol. Specifically, previous data demonstrated
that ixmyelocel-T macrophages expressed lower levels
of scavenger receptors involved in modified cholesterol












cholesterol efflux was examined in SCID mice after intraperitoneal
sma 3H-cholesterol levels after 24 and 48 hours, (B) 3H-tracer found in
p). Values are presented as mean ± SEM relative to control, *P < 0.05
of the mean.
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sion of these surface receptors in the presence of modified
lipids. Fluorescence microscopy and flow cytometry dem-
onstrated that ixmyelocel-T macrophages exhibited accu-
mulation of modified LDL, showing that they do indeed
influx modified cholesterol. However, fluorescence mi-
croscopy suggested that ixmyelocel-T macrophages do
not store large pools of cholesterol esters, suggesting that
a majority of this cholesterol remains in the free state
ready for efflux.
These data suggest that the macrophages generated
by ixmyelocel-T may use protective mechanisms to pre-
vent uncontrolled cholesterol loading, which is toxic to
macrophages. These results suggest that ixmyelocel-T
macrophages use a protective mechanism against un-
regulated modified cholesterol uptake by not upregula-
ting scavenger receptor expression in the presence of
modified cholesterol, as well as not storing vast amounts
as esters. This observation is in alignment with the re-
duced apoptosis found in ixmyelocel-T macrophages
after cholesterol loading and the minimal increase in
pro-inflammatory cytokine secretion after lipid loading
and inflammatory challenge. The relatively low ex-
pression of scavenger receptors after modified choles-
terol loading is one potential mechanism by which
ixmyelocel-T is protected from cellular apoptosis after
high lipid loading.
ACAT-1 promotes accumulation of intracellular CE
in macrophages [33]. Studies have demonstrated that
ACAT-1 plays an important role in atherosclerosis and
is expressed at elevated levels in foam cells located
within atherosclerotic lesions [7,33]. In addition, studies
have also demonstrated that reduced ACAT-1 expres-
sion has been reported to inhibit foam cell formation in
macrophages [33]. The results of this study show that a
statistically significant decrease in ACAT-1 expression
occurred in ixmyelocel-T macrophages when compared
with THP-1 macrophages. Moreover, after loading
with Ac-LDL, expression of ACAT-1 was not increased in
ixmyelocel-T macrophages, a feature THP-1 macrophages
did not share.
Hydrolysis of stored CE is the first and rate-limiting
step in cholesterol efflux from macrophage foam cells,
and increased expression of CEH leads to increased
mobilization of CE, thereby decreasing lipid accumu-
lation [9]. After loading with modified cholesterol,
ixmyelocel-T macrophages exhibited increased CEH ex-
pression, the expression of which was decreased in
THP-1 macrophages. These results may explain why the
fluorescence microscopy images indicated that ixmye-
locel-T macrophages do not store large pools of cho-
lesterol esters. A decrease in ACAT-1 and increase in
CEH would suggest that a majority of the ingested cho-
lesterol remains in the free state, ready for efflux. Thecombination of both increased CEH and decreased
ACAT-1 expression after cholesterol loading may be one
mechanism by which ixmyelocel-T macrophages reduce
cholesterol accumulation, thus preventing lipotoxicity.
Macrophages maintain cholesterol homeostasis with a
balance between influx and efflux pathways [5]. To
appreciate the potential impact of ixmyelocel-T macro-
phages on cholesterol homeostasis, it is essential to con-
sider all aspects of cholesterol homeostasis, including
efflux from cells. This investigation demonstrated that
ixmyelocel-T macrophages display enhanced cholesterol
efflux capacity. Specifically, these data demonstrated that
after loading with Ac-LDL, ixmyelocel-T macrophages
upregulated expression of both cholesterol transporter
genes, ABCA1 and ABCG1. Both of these transporters
are critical in the efflux of cholesterol from macro-
phages. In addition, results from the cholesterol efflux
assay revealed that ixmyelocel-T macrophages were not
only able to efflux cholesterol to the acceptor ApoAI
and HDL3, but also to perform this action at an en-
hanced level. Ixmyelocel-T macrophages were also able
to perform this action in vivo in the RCT assay.
Taken together, these data highlight the enhanced abi-
lity of ixmyelocel-T to promote RCT through cholesterol
influx and efflux. In addition, the results highlight one
mechanism by which ixmyelocel-T macrophages main-
tain cholesterol homeostasis.
Atherosclerosis is chronic inflammatory disease that
leads to a multitude of diseases, including coronary ar-
tery disease, peripheral artery disease, and stroke [34].
Several therapies have been investigated in atheros-
clerosis, including antiinflammatory drugs, cytokine, and
chemokine antagonists. However, no really promising ef-
fects on clinical outcomes have been seen on the reduc-
tion of atherosclerosis in CAD [34]. Cell therapies have
emerged for the treatment of cardiovascular diseases.
Several studies have also provided evidence that cell
therapies could be a useful treatment in of atheroscler-
osis, promoting lesion regression and thereby improving
vascular health [34-36]. Furthermore, several studies
have demonstrated that atherosclerotic lesions contain
both M1 and M2 macrophages, providing evidence that
M1 macrophages are found in unstable rupture-prone
regions of atherosclerotic plaques [37-39]. Therefore,
ixmyelocel-T may be potentially beneficial in the treat-
ment of atherosclerotic disease states in which they
might promote lesion regression or stabilization through
immunomodulation, efferocytosis, and modified choles-
terol removal. Treatment with ixmyelocel-T has been in-
vestigated in bone regeneration, critical limb ischemia,
and ischemic DCM. Further analysis of the subpopula-
tions of cells generated in ixmyelocel-T could highlight
new and innovative uses of this multicellular therapy. In
this case, further analysis of ixmyelocel-T macrophages
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be advantageous in disease states involving atheroscle-
rotic lesions, which would benefit from immunomodu-
lation, efferocytosis, and modified cholesterol removal.
Future studies will examine the effects of ixmyelocel-T
in preclinical models to determine whether this therapy
can affect the atherosclerotic state. For this cell therapy
to affect an atheroma, it might need to be present in the
lesion itself. Therefore, future studies will examine whe-
ther ixmyelocel-T has the ability to infiltrate atheroscle-
rotic lesions or if it must be directly injected into areas
where it might have the potential to dampen the immune
response, remove necrotic debris, and efflux cholesterol.
Conclusion
The present data provide evidence that ixmyelocel-T has
the potential to become an effective adjuvant in the
treatment of diseases due to atherosclerosis. Ixmyelocel-T
contains a unique M2-like population of macrophages
that are efficient at efferocytosis and maintaining choles-
terol homeostasis. The data presented here suggest that
ixmyelocel-T macrophages may exert beneficial effects in
atherosclerotic disease because they influx cholesterol, re-
main antiinflammatory in the face of lipid loading and in-
flammatory challenge, and display enhanced cholesterol
efflux capabilities. The multifactorial characteristics of the
ixmyelocel-T M2-like macrophages described in this ana-
lysis, as well as the companion manuscript presented in
Stem Cell Research and Therapy, highlight the potential
effectiveness of this expanded autologous multicellular
therapy in the treatment of atherosclerotic diseases.
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